0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > ALPG

ALPG

Brief Information

Name:Alkaline phosphatase
Target Synonym:Alkaline Phosphatase
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ALG-H52H9-ELISA
 ALPG ELISA

Immobilized Human ALPG, His Tag (Cat. No. ALG-H52H9) at 1 μg/mL (100 μL/well) can bind Anti - ALPG / ALPPL2 with a linear range of 0.002-0.125 μg/mL (QC tested).

ALG-H52E1-MALS-HPLC
ALPG MALS images

The purity of Biotinylated Human ALPG Protein, His,Avitag (Cat. No. ALG-H52E1) is more than 90% and the molecular weight of this protein is around 115-135 kDa verified by SEC-MALS.

Synonym Name

ALPG,GCAP,ALP-1,ALPPL2,PLAP-like,ALPPL,Alkaline phosphatase, germ cell type

Background

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Amifostine NSC-296961; YM-08310; S-8744; SAPEP; WR-2721; WR-2721C Approved Medimmune Llc 天地达, 安福定, Ethyol United States Head and Neck Neoplasms; Ovarian Neoplasms Clinigen Inc 1995-12-08 Cytoprotective adjuvant; Myelodysplastic-Myeloproliferative Diseases; Salivary Gland Diseases; Mucositis; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Bone Marrow Diseases; Sarcoma; Acute Radiation Syndrome; Breast Neoplasms; Prostatic Neoplasms; Gestational Trophoblastic Disease; Radiation Injuries; Head and Neck Neoplasms; Nasopharyngeal Neoplasms; Fanconi Anemia; Hodgkin Disease; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Neutropenia; Carcinoma; Peripheral Nervous System Diseases; Trigeminal Neuralgia; Solid tumours; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions Details
Amifostine NSC-296961; YM-08310; S-8744; SAPEP; WR-2721; WR-2721C Approved Medimmune Llc 天地达, 安福定, Ethyol United States Head and Neck Neoplasms; Ovarian Neoplasms Clinigen Inc 1995-12-08 Cytoprotective adjuvant; Myelodysplastic-Myeloproliferative Diseases; Salivary Gland Diseases; Mucositis; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Bone Marrow Diseases; Sarcoma; Acute Radiation Syndrome; Breast Neoplasms; Prostatic Neoplasms; Gestational Trophoblastic Disease; Radiation Injuries; Head and Neck Neoplasms; Nasopharyngeal Neoplasms; Fanconi Anemia; Hodgkin Disease; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Neutropenia; Carcinoma; Peripheral Nervous System Diseases; Trigeminal Neuralgia; Solid tumours; Ovarian Neoplasms; Drug-Related Side Effects and Adverse Reactions Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ALXN-1850 ALXN-1850 Phase 3 Clinical Alexion Pharmaceuticals Inc Hypophosphatasia Details
ALXN-1850 ALXN-1850 Phase 3 Clinical Alexion Pharmaceuticals Inc Hypophosphatasia Details

This web search service is supported by Google Inc.

totop

Laisser un message